Please use this identifier to cite or link to this item:
|Title:||Successful clearance of human parainfluenza virus type 2 viraemia with intravenous ribavirin and immunoglobulin in a patient with acute myocarditis||Authors:||Kalimuddin, S.
|Keywords:||Human parainfluenza virus
|Issue Date:||Jan-2013||Citation:||Kalimuddin, S., Sessions, O.M., Hou, Y., Ooi, E.E., Sim, D., Cumaraswamy, S., Tan, T.E., Lai, S.H., Low, C.Y. (2013-01). Successful clearance of human parainfluenza virus type 2 viraemia with intravenous ribavirin and immunoglobulin in a patient with acute myocarditis. Journal of Clinical Virology 56 (1) : 37-40. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jcv.2012.10.005||Abstract:||Human parainfluenza virus (HPIV) infection as an aetiology of acute viral myocarditis is rare, with only few cases reported in the literature to date. Here we report a case of fulminant HPIV-2 myocarditis in a 47 year-old man with viraemia who was successfully treated with intravenous ribavirin and intravenous immunoglobulin (IVIG). There are currently no recommendations on the treatment of HPIV myocarditis. We are, to our knowledge, the first to report a patient with a documented HPIV-2 viraemia that subsequently cleared after the initiation of antiviral therapy. Although it is difficult to definitively attribute the patient's clinical improvement to ribavirin or IVIG alone, our case does suggest that clinicians may wish to consider initiating ribavirin and IVIG in patients with HPIV myocarditis and persistent viraemia not responding to supportive measures alone. © 2012 Elsevier B.V.||Source Title:||Journal of Clinical Virology||URI:||http://scholarbank.nus.edu.sg/handle/10635/126597||ISSN:||13866532||DOI:||10.1016/j.jcv.2012.10.005|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Aug 5, 2020
WEB OF SCIENCETM
checked on Jul 28, 2020
checked on Jul 31, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.